(UroToday.com) The best abstract oncology session at the virtual EAU 2020 meeting featured second place winner Dr. Paul Sargos discussing late toxicity and quality of life from the GETUG-AFU 22 study. Currently, no recommendations exist for patients with immediate detectable prostate specific antigen (PSA) after radical prostatectomy. The purpose of the GETUG-AFU 22 study was to compare the toxicity and quality of life results in adding hormone therapy to radiotherapy for patients with detectable PSA after radical prostatectomy.